Disclosure

 

 

Update: For temporary changes to publication of 2019 Data on Disclosure UK in June 2020 please refer to the the ABPI website.

The links to the Disclosure template forms for the submission of 2018 data and for the submission of previous data (2016 and 2017) are both available to download from Publications. The changes made to the disclosure template in March 2019 are outlined below.

Following the publication of the 2019 Code of Practice for the Pharmaceutical Industry a new ABPI disclosure template must now be used by companies making disclosures of transfers of value to healthcare professionals (HCPs) and healthcare organisations (HCOs) for 2018.The following changes and requirements are included in the new template: 

▪ Make the link to the executive summary optional for inclusion in the template. If the link is not in the template it must be included in the methodological note (as required by Clause 24.1).
▪ Removal of the option to put payments to healthcare organisations in aggregate.
▪ To require companies to provide totals (previously optional) and to add notes to make it clear what is required. A warning has also been added to remind companies that individuals might appear in more than one of the categories, ie receive a fee for service and expenses.
▪ To add notes to make it clear that data in columns headed ‘registration fees’, ‘travel and accommodation’, ‘fees for service’ and ‘related expenses agreed’ relate to that column.

▪ To add a note to make it clear that the methodological note must include the number of individuals who have agreed to some payments being disclosed individually and others in aggregate.

Please note that some browsers (such as Internet Explorer) will request credentials, so either use an alternative browser (such as Chrome) or click through the request for access to all templates. 

Guidance on Methodological Notes, updated in January 2019 for relevant data, can be found here.

For more information about making disclosures of transfers of value on Disclosure UK, please contact the ABPI’s disclosure team at disclosure@abpi.org.uk.

...............................................................................................................................................................................................................................

Previous Press Releases: 
30 June 2018
2017 Disclosure Data published by the ABPI 

The ABPI has published the data on Disclosure UK – the pharmaceutical industry’s database of payments and benefits in kind made to UK healthcare professionals (HCPs) and organisations (HCOs). For further details please see the ABPI press release.

In 2017 pharmaceutical companies disclosed details of certain transfers of value made during the year to named health professionals, other relevant decision makers and health organisations on a central platform.  The 2017 data has now been disclosed.  

Further details can be found in the ABPI Code of Practice for the Pharmaceutical Industry (see Clause 24 and others) and on the ABPI and PMCPA websites. 

The ABPI Disclosure template can be found here​ and the then current guidance on the methodological note (since updated in January 2019) can be found here.

..............................................................................................................................................................................................................................

30 June 2017
​​​Today the ABPI is publishing the 2016 data, for further details please see the ABPI press release.
​​​In 2016 pharmaceutical companies disclosed details of certain transfers of value to named health professionals, other relevant decision makers and health organisations made during 2015 on a central platform.  The 2016 data has now been disclosed.  Further details can be found in the ABPI Code (see Clause 24 and others) and on the ABPI and PMCPA websitesThe ABPI Disclosure template can be found hereGuidance on the methodological note can be found here.
 
In November 2015 further details about the arrangements were sent to pharmaceutical companies – including the data sharing agreement - to sign and return to the ABPI as soon as possible.​